Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease

World Journal of Gastroenterology

Volumn 21, Issue 19, 2015, Pages 6072-6076

  Moran, Neil R ^a   Webster, Bradley ^a   Lee, Kenneth M ^a   Trotman, Judith ^a   Kwan, Yiu Lam ^a   Napoli, John ^b   Leong, Rupert W ^a  

^a ANZAC Research Institute   (Australia)

^b Pennant Hills Endoscopy   (Australia)

Author keywords

Crohn's disease; Epstein Barr virus; Hodgkin lymphoma; Inflammatory bowel disease; Mucocutaneous ulcer

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; VINBLASTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COLON BIOPSY; COLON RESECTION; COLON ULCER; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER OF THE COLON; FEMALE; FEVER; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; INTESTINE ANASTOMOSIS; LIVER INJURY; MIDDLE AGED; MONONUCLEOSIS; NAUSEA; OUTCOME ASSESSMENT; RECTUM HEMORRHAGE; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT REFUSAL; TREATMENT RESPONSE; BIOPSY; COLONIC NEOPLASMS; DISEASE COURSE; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; GASTROINTESTINAL HEMORRHAGE; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; TIME FACTOR; TREATMENT OUTCOME; ULCER; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; COLECTOMY; COLONIC NEOPLASMS; COLONOSCOPY; CROHN DISEASE; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; ILEOSTOMY; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; ULCER;

EID: 84929615487     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i19.6072     Document Type: Article

References (20)

1. Ling PD, Lednicky JA, Keitel WA, Poston DG, White ZS, Peng R, Liu Z, Mehta SK, Pierson DL, Rooney CM, Vilchez RA, Smith EO, Butel JS. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 2003;187:1571-1580 [PMID: 12721937 DOI: 10.1086/374739]
2. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-1337 [PMID: 15044644 DOI: 10.1056/NEJMra032015]
3. Ng SB, Khoury JD. Epstein-Barr virus in lymphoproliferative processes: an update for the diagnostic pathologist. Adv Anat Pathol 2009;16:40-55 [PMID: 19098466 DOI: 10.1097/PAP.0b013e3181916029]
4. Magro F, Santos-Antunes J, Albuquerque A, Vilas-Boas F, Macedo GN, Nazareth N, Lopes S, Sobrinho-Simões J, Teixeira S, Dias CC, Cabral J, Sarmento A, Macedo G. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens. Inflamm Bowel Dis 2013;19:1710-1716 [PMID: 23574759]
5. Allen PB, Laing G, Connolly A, O'Neill C. EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem? BMJ Case Rep 2013;2013:bcr2013200423 [PMID: 24081592 DOI: 10.1136/bcr-2013-200423]
6. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer-a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010;34:405-417 [PMID: 20154586 DOI: 10.1097/PAS.0b013e3181cf8622]
7. Sadasivam N, Johnson RJ, Owen RG. Resolution of methotrexateinduced Epstein-Barr virus-associated mucocutaneous ulcer. Br J Haematol 2014;165:584 [PMID: 24456137 DOI: 10.1111/bjh.12743]
8. Hashizume H, Uchiyama I, Kawamura T, Suda T, Takigawa M, Tokura Y. Epstein-Barr virus-positive mucocutaneous ulcers as a manifestation of methotrexate-associated B-cell lymphoproliferative disorders. Acta Derm Venereol 2012;92:276-277 [PMID: 22293895 DOI: 10.2340/00015555-1274]
9. McGinness JL, Spicknall KE, Mutasim DF. Azathioprine-induced EBV-positive mucocutaneous ulcer. J Cutan Pathol 2012;39:377-381 [PMID: 22236092 DOI: 10.1111/j.1600-0560.2011.01829. x]
10. Subramaniam K, Cherian M, Jain S, Latimer M, Corbett M, D'Rozario J, Pavli P. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications. Intern Med J 2013;43:1339-1342 [PMID: 24330365 DOI: 10.1111/imj.12287]
11. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978;42:693-707 [PMID: 354774]
12. Thomas DB, Huston BM, Lamm KR, Maia DM. Primary Hodgkin's disease of the sigmoid colon: a case report and review of the literature. Arch Pathol Lab Med 1997;121:528-532 [PMID: 9167612]
13. Kumar S, Fend F, Quintanilla-Martinez L, Kingma DW, Sorbara L, Raffeld M, Banks PM, Jaffe ES. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 2000;24:66-73 [PMID: 10632489 DOI: 10.1097/0000047 8-200001000-00008]
14. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-565 [PMID: 7812011]
15. Sokol H, Beaugerie L, Maynadie M, Laharie D, Dupas JL, Flourie B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2063-2071 [PMID: 22271569 DOI: 10.1002/ibd.22889]
16. Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis. Clin Gastroenterol Hepatol 2015;13:847-858. e4 [PMID: 24879926 DOI: 10.1016/j.cgh.2014.05.015]
17. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108:99-105 [PMID: 23032984 DOI: 10.1038/ajg.2012.334]
18. Flynn AD, Azar JM, Chiorean MV. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn's disease. Inflamm Bowel Dis 2013;19:E69-E70 [PMID: 23399737]
19. Glocker E, Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency? Cell Mol Life Sci 2012;69:41-48 [PMID: 21997382 DOI: 10.1007/s00018-011-0837-9]
20. Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014;20:3255-3264 [PMID: 24695798 DOI: 10.3748/wjg.v20.i12.3255]